Table 1 Demographic and clinical characteristics of diabetic and non-diabetic patients treated with either linezolid or vancomycin for MRSA-nosocomial pneumonia in the modified intent to treat (MITT) population
Diabetic Patients (N = 183) | Non-diabetic Patients (N = 265) | |||
|---|---|---|---|---|
Characteristic | Linezolid N = 87 | Vancomycin N = 96 | Linezolid N = 137 | Vancomycin N = 128 |
Age (y), mean (SD) *** | 67.1 (13.0) | 69.8 (12.8) | 58.2 (19.8) | 56.1 (19.3) |
Male Sex, n (%) | 57 (65.5) | 55 (57.3) | 94 (68.6) | 88 (68.8) |
Race, n (%) | ||||
White | 59 (67.8) | 60 (62.5) | 97 (70.8) | 92 (71.9) |
Black | 11 (12.6) | 15 (15.6) | 14 (10.2) | 16 (12.5) |
Asian | 12 (13.8) | 17 (17.7) | 20 (14.6) | 16 (12.5) |
Other | 5 (5.7) | 4 (4.2) | 6 (4.4) | 4 (3.1) |
Treatment duration (days), mean (SD) | 9.7 (4.1) | 9.1 (4.9) | 10.1 (3.8) | 10.0 (4.1) |
Baseline blood glucose (mg/dl), na/mean (SD) | 83/176.3 (116.7) | 91/167.8 (123.5) | 129/164.7 (152.7) | 121/174.9 (158.9) |
Bacteremia, n (%) | ||||
Yes | 6 (6.9) | 10 (10.4) | 9 (6.6) | 14 (10.9) |
No | 78 (89.7) | 85 (88.5) | 116 (84.7) | 110 (85.9) |
Unknown | 3 (3.4) | 1 (1.0) | 12 (8.8) | 4 (3.1) |
Insulin at Baseline n (%) | 58 (66.7) | 74 (77.1) | N/A | N/A |
Ventilated at baseline, n (%) | 58 (66.7) | 70 (72.9) | 95 (69.3) | 93 (72.7) |
APACHE Score, n (%) *** | ||||
< 20 | 50 (57.5) | 52 (54.2) | 91 (66.4) | 87 (68.0) |
≥ 20 | 36 (41.4) | 42 (43.8) | 43 (31.4) | 39 (30.5) |
Unknown | 1 (1.1) | 2 (2.1) | 3 (2.2) | 2 (1.6) |
CPIS score, na/mean (SD) Baseline | 56/9.6 (2.2) | 63/9.5 (2.1) | 89/9.5 (2.1) | 91/9.2 (2.4) |
Chest x-ray, n (%)b | ||||
Unilateral | 20 (23.0) | 29 (30.2) | 39 (28.5) | 50 (39.1) |
Bilateral | 65 (74.7) | 67 (69.8) | 98 (71.5) | 78 (60.9) |
Pleural effusion, n (%) | 42 (48.3) | 38 (39.6) | 63 (46.0) | 58 (45.3) |
Weight (kg), na/mean (SD) *** | 87/85.6 (26.8) | 96/79.2 (22.4) | 137/73.2 (18.0) | 127/76.2 (20.4) |
Comorbidities, n (%) | ||||
Cardiac *** | 58 (66.7) | 69 (71.9) | 73 (53.3) | 68 (53.1) |
Hepatobiliary | 13 (14.9) | 10 (10.4) | 21 (15.3) | 21 (16.4) |
Gastrointestinal *** | 57 (65.5) | 56 (58.3) | 71 (51.8) | 63 (49.2) |
Neoplastic | 8 (9.2) | 13 (13.5) | 12 (8.8) | 12 (9.4) |
Renal/Urinary *** | 40 (46.0) | 53 (55.2) | 43 (31.4) | 41 (32.0) |
Pulmonary | 65 (74.7) | 67 (69.8) | 87 (63.5) | 87 (68.0) |
Vascular *** | 38 (43.7) | 37 (38.5) | 38 (27.7) | 41 (32.0) |
Baseline pathogens, n (%) | ||||
MRSA only | 53 (60.9) | 62 (64.6) | 66 (48.2) | 66 (51.6) |
MRSA + other Gr (+) | 6 (6.9) | 9 (9.4) | 16 (11.7) | 9 (7.0) |
MRSA + other Gr (-) | 19 (21.8) | 18 (18.8) | 41 (29.9) | 38 (29.7) |
MRSA+ other Gr (+) and Gr (-) | 5 (5.7) | 3 (3.1) | 8 (5.8) | 10 (7.8) |
MRSA + anaerobes | 0 | 1 (1.0) | 0 | 1 (0.8) |
MRSA + fungal | 4 (4.6) | 3 (3.1) | 6 (4.4) | 4 (3.1) |
Baseline Vancomycin MICs, n (%) | ||||
≤ 0.5 | 7 (8.0) | 2 (2.1) | 10 (7.3) | 12 (9.4) |
1 | 63 (72.4) | 75 (78.1) | 105 (76.6) | 93 (72.7) |
2 | 7 (8.0) | 7 (7.3) | 6 (4.4) | 11 (8.6) |
4 | 0 | 1 (1.0) | 0 | 1 (0.8) |
unknown | 10 (11.5) | 11 (11.5) | 16 (11.7) | 11 (8.6) |